Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia

Can J Neurol Sci. 2022 Jan;49(1):123-128. doi: 10.1017/cjn.2021.42. Epub 2021 Mar 9.

Abstract

We investigated the effects of botulinum toxin on gait in Parkinson's disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain, Timed Up and Go (TUG), Berg Balance Test (BBT), and 3D gait analysis at baseline, 1 month, and 3 months. BFMDRS (p = 0.002), VAS (p = 0.024), TUG (p = 0.028), and BBT (p = 0.034) were improved. Foot pressures at Toe 1 (p = 0.028) and Midfoot (p = 0.018) were reduced, indicating botulinum toxin's effects in alleviating the dystonia severity and pain and improving foot pressures during walking in PD.

Keywords: Botulinum toxin A; Foot dystonia; Gait; Parkinson’s disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Dystonia* / drug therapy
  • Gait
  • Humans
  • Parkinson Disease* / complications
  • Parkinson Disease* / drug therapy
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A
  • onabotulinum toxin A